172 related articles for article (PubMed ID: 27569996)
1. The pattern of GPI-80 expression is a useful marker for unusual myeloid maturation in peripheral blood.
Takeda Y; Kato T; Ito H; Kurota Y; Yamagishi A; Sakurai T; Araki A; Nara H; Tsuchiya N; Asao H
Clin Exp Immunol; 2016 Dec; 186(3):373-386. PubMed ID: 27569996
[TBL] [Abstract][Full Text] [Related]
2. Expression of GPI-80, a beta2-integrin-associated glycosylphosphatidylinositol-anchored protein, requires neutrophil differentiation with dimethyl sulfoxide in HL-60 cells.
Takeda Y; Fu J; Suzuki K; Sendo D; Nitto T; Sendo F; Araki Y
Exp Cell Res; 2003 Jun; 286(2):199-208. PubMed ID: 12749849
[TBL] [Abstract][Full Text] [Related]
3. GPI-80 as a Useful Index for Myeloid Cell Heterogeneity and a Potential Prognostic Biomarker for Metastatic Renal Cell Carcinoma.
Kato T; Takeda Y; Ito H; Kurota Y; Yamagishi A; Sakurai T; Naito S; Araki A; Nara H; Asao H; Tsuchiya N
Tohoku J Exp Med; 2019 Nov; 249(3):203-212. PubMed ID: 31776298
[TBL] [Abstract][Full Text] [Related]
4. Human Isogenic Cell Line Models for Neutrophils and Myeloid-Derived Suppressor Cells.
Zhang Y; Wilt E; Lu X
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081041
[TBL] [Abstract][Full Text] [Related]
5. [Recombinant HMGB1 induces the differentiation of mouse myeloid cells into myeloid-derived suppressor cells in vitro].
Su Z; Zhang Y; Ni P; Wang J
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Oct; 32(10):1362-1365. PubMed ID: 27667463
[TBL] [Abstract][Full Text] [Related]
6. Tumor-associated GM-CSF overexpression induces immunoinhibitory molecules via STAT3 in myeloid-suppressor cells infiltrating liver metastases.
Thorn M; Guha P; Cunetta M; Espat NJ; Miller G; Junghans RP; Katz SC
Cancer Gene Ther; 2016 Jun; 23(6):188-98. PubMed ID: 27199222
[TBL] [Abstract][Full Text] [Related]
7. A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients.
Vetsika EK; Koinis F; Gioulbasani M; Aggouraki D; Koutoulaki A; Skalidaki E; Mavroudis D; Georgoulias V; Kotsakis A
J Immunol Res; 2014; 2014():659294. PubMed ID: 25436215
[TBL] [Abstract][Full Text] [Related]
8. p120 nucleolar-proliferating antigen is a direct target of G-CSF signaling during myeloid differentiation.
Khanna-Gupta A; Sun H; Zibello T; Lozovatsky L; Ghosh PK; Link DC; McLemore ML; Berliner N
J Leukoc Biol; 2006 May; 79(5):1011-21. PubMed ID: 16641140
[TBL] [Abstract][Full Text] [Related]
9. IFN regulatory factor 8 represses GM-CSF expression in T cells to affect myeloid cell lineage differentiation.
Paschall AV; Zhang R; Qi CF; Bardhan K; Peng L; Lu G; Yang J; Merad M; McGaha T; Zhou G; Mellor A; Abrams SI; Morse HC; Ozato K; Xiong H; Liu K
J Immunol; 2015 Mar; 194(5):2369-79. PubMed ID: 25646302
[TBL] [Abstract][Full Text] [Related]
10. Localization of GPI-80, a beta2-integrin-associated glycosylphosphatidyl-inositol anchored protein, on strongly CD14-positive human monocytes.
Sendo D; Takeda Y; Ishikawa H; Sendo F; Araki Y
Immunobiology; 2003; 207(3):217-21. PubMed ID: 12777063
[TBL] [Abstract][Full Text] [Related]
11. Conditioned media from the renal cell carcinoma cell line 786.O drives human blood monocytes to a monocytic myeloid-derived suppressor cell phenotype.
Okada SL; Simmons RM; Franke-Welch S; Nguyen TH; Korman AJ; Dillon SR; Gilbertson DG
Cell Immunol; 2018 Jan; 323():49-58. PubMed ID: 29103587
[TBL] [Abstract][Full Text] [Related]
12. Granulocyte-macrophage colony-stimulating factor and other cytokines regulate surface expression of the leukocyte adhesion molecule-1 on human neutrophils, monocytes, and their precursors.
Griffin JD; Spertini O; Ernst TJ; Belvin MP; Levine HB; Kanakura Y; Tedder TF
J Immunol; 1990 Jul; 145(2):576-84. PubMed ID: 1694883
[TBL] [Abstract][Full Text] [Related]
13. Circulating myeloid-derived suppressor cells in patients with pancreatic cancer.
Xu XD; Hu J; Wang M; Peng F; Tian R; Guo XJ; Xie Y; Qin RY
Hepatobiliary Pancreat Dis Int; 2016 Feb; 15(1):99-105. PubMed ID: 26818550
[TBL] [Abstract][Full Text] [Related]
14. Tumor-induced myeloid-derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+ T-cell activation events.
Schouppe E; Mommer C; Movahedi K; Laoui D; Morias Y; Gysemans C; Luyckx A; De Baetselier P; Van Ginderachter JA
Eur J Immunol; 2013 Nov; 43(11):2930-42. PubMed ID: 23878002
[TBL] [Abstract][Full Text] [Related]
15. On the origin of myeloid-derived suppressor cells.
Millrud CR; Bergenfelz C; Leandersson K
Oncotarget; 2017 Jan; 8(2):3649-3665. PubMed ID: 27690299
[TBL] [Abstract][Full Text] [Related]
16. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF.
Dolcetti L; Peranzoni E; Ugel S; Marigo I; Fernandez Gomez A; Mesa C; Geilich M; Winkels G; Traggiai E; Casati A; Grassi F; Bronte V
Eur J Immunol; 2010 Jan; 40(1):22-35. PubMed ID: 19941314
[TBL] [Abstract][Full Text] [Related]
17. Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells.
Donkor MK; Lahue E; Hoke TA; Shafer LR; Coskun U; Solheim JC; Gulen D; Bishay J; Talmadge JE
Int Immunopharmacol; 2009 Jul; 9(7-8):937-48. PubMed ID: 19362167
[TBL] [Abstract][Full Text] [Related]
18. Assessment of myeloid-derived suppressor cell differentiation ex vivo.
Blanco E; Escors D; Kochan G
Methods Cell Biol; 2024; 184():85-96. PubMed ID: 38555160
[TBL] [Abstract][Full Text] [Related]
19. Identification of granulocytic myeloid-derived suppressor cells (G-MDSCs) in the peripheral blood of Hodgkin and non-Hodgkin lymphoma patients.
Marini O; Spina C; Mimiola E; Cassaro A; Malerba G; Todeschini G; Perbellini O; Scupoli M; Carli G; Facchinelli D; Cassatella M; Scapini P; Tecchio C
Oncotarget; 2016 May; 7(19):27676-88. PubMed ID: 27050283
[TBL] [Abstract][Full Text] [Related]
20. Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy.
Ornstein MC; Diaz-Montero CM; Rayman P; Elson P; Haywood S; Finke JH; Kim JS; Pavicic PG; Lamenza M; Devonshire S; Dann P; Schach K; Stephenson A; Campbell S; Emamekhoo H; Ernstoff MS; Hoimes CJ; Gilligan TD; Rini BI; Garcia JA; Grivas P
Urol Oncol; 2018 Sep; 36(9):405-412. PubMed ID: 29606341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
